Category: Research
Three-year overall survival with nivolumab plus relatlimab in advanced melanoma from RELATIVITY-047
Nivolumab plus relatlimab demonstrated a statistically significant improvement in progression-free survival (PFS), along with a clinically meaningful, but not statistically significant improvement in …
Effectiveness of cross-sector collaboration in strategy implementation and impact: Evaluation of the NSW Skin Cancer Prevention Strategy 2016-2022
Issues addressed: Australia continues to have one of the highest rates of skin cancer in the world. In NSW, melanoma is the third most common cancer diagnosed. At least 95% of skin cancers are caused…
Prognostic significance of miRNA subtypes in melanoma
Background and Objectives: Melanoma remains a leading cause of skin cancer mortality despite advancements in targeted therapies and immunotherapies. MicroRNAs (miRNAs) have emerged as potential bioma…
Read more about 'Prognostic significance of miRNA subtypes in melanoma'...
0.8-mm threshold for guiding the care of patients with thin primary melanomas
Importance: Most patients who present with primary cutaneous melanomas have thin tumors (≤1.0 mm in Breslow thickness, ie, pT1a and pT1b). Although their prognosis is generally considered to be excel…
Read more about '0.8-mm threshold for guiding the care of patients with thin primary melanomas'...
Outcomes following long-term disease control with immune checkpoint inhibitors in patients with advanced melanoma
Immune checkpoint inhibitors (ICI) can achieve durable responses in patients with advanced melanoma, and results from clinical trials suggest cure may be possible for a subset of patients. Despite cli…
Treatment sequence with tebentafusp and immune checkpoint inhibitors in patients with metastatic uveal melanoma and metastatic GNA11/GNAQ mutant melanocytic tumors
Background: Metastatic uveal melanoma (mUM) is rare. Immune checkpoint inhibitors (ICIs) have shown modest efficacy in mUM. Tebentafusp prolonged overall survival (OS) in a phase 3 study. We aimed to …
Improved survival of advanced melanoma patients receiving immunotherapy with concomitant antithrombotic therapy
Background: Cancer immunotherapy has revolutionized melanoma treatment, but the high number of non-responders still emphasizes the need for improvement of therapy. One potential avenue for enhancing a…
Circulating tumor DNA assessment shows promising results in predicting and reflecting disease status during adjuvant therapy
Background: The introduction of adjuvant therapies for patients with resected cutaneous melanoma (CM) has increased the need for sensitive biomarkers for risk stratification and disease monitoring. Th…
Melacare nurse-led intervention feasible and acceptable for use with patients treated for early-stage melanoma
Background and purpose: We developed the Melacare nurse-led intervention, which combines education in skin self-examination as a resource-conscious approach to detecting recurrence and management of …
PDE4D drives rewiring of MAPK pathway in BRAF-mutated melanoma resistant to MAPK inhibitors
Background: Phosphodiesterase type 4D (PDE4D) breaks down cyclic AMP (cAMP) reducing the signaling of this intracellular second messenger which plays a major role in melanocyte pathophysiology. In adv…